Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Tissue regulatory T cells: regulatory chameleons

Muñoz-Rojas AR., Mathis D.

Narrative Review on Systemic / IV, published in Nat Rev Immunol (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Nat Rev Immunol (2021)
Reported sample size
—
Source database
Europe PMC
PMID
33772242
PMCID
PMC8403160
DOI
10.1038/s41577-021-00519-w
Citations
223

Abstract (original English)

The FOXP3 + CD4 + regulatory T (T reg ) cells located in non-lymphoid tissues differ in phenotype and function from their lymphoid organ counterparts. Tissue T reg cells have distinct transcriptomes, T cell receptor repertoires and growth and survival factor dependencies that arm them to survive and operate in their home tissue. Their functions extend beyond immune surveillance to tissue homeostasis, including regulation of local and systemic metabolism, promotion of tissue repair and regeneration, and control of the proliferation, differentiation and fate of non-lymphoid cell progenitors. T reg cells in diverse tissues share a common FOXP3 + CD4 + precursor located within lymphoid organs. This precursor undergoes definitive specialization once in the home tissue, following a multilayered array of common and tissue-distinct transcriptional programmes. Our deepening knowledge of tissue T reg cell biology will inform ongoing attempts to harness T reg cells for precision immunotherapeutics.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Muscle, SkeletalSkinAnimalsHumansMiceReceptors, Antigen, T-CellHomeostasisModels, ImmunologicalFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research